查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594439

新抗原標靶治療治療市場：按目標疾病、新抗原類型、免疫治療類型、給藥途徑途徑- 全球預測 2025-2030

Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

新抗原標靶治療治療市場2023年估值為33.1億美元，預計2024年將達45.8億美元，複合年成長率為38.52%，預計到2030年將達到324.1億美元。

新抗原標靶治療專注於利用因腫瘤特異性突變而在癌細胞中特異性表達的新抗原來創建個人化癌症疫苗和過繼性 T 細胞療法。對這些治療方法的需求是巨大的，因為與傳統療法相比，它們有可能減少脫靶效應並提高特異性和療效。治療方法適用於個人化醫療，並根據基因圖譜為每位患者量身定做。最終用途包括醫院、癌症研究中心和從事大規模臨床應用的製藥公司。影響該市場的主要成長要素包括癌症盛行率的增加、基因組技術的進步以及個人化醫療投資的增加。擴大採用次世代定序和生物資訊工具來增強新抗原的識別，這是一個重大的商機。製藥公司和研究機構應注重策略合作，有效利用生物資訊能力和基因組資料庫來最佳化新抗原的預測和檢驗。然而，治療成本上升、新抗原識別的複雜性以及嚴格的法律規範等挑戰可能會阻礙市場成長。克服這些障礙需要創新，特別是在自動化生物資訊分析和具有成本效益的生產技術方面，以提高可及性。對高度自適應人工智慧/機器學習模型的投資可以徹底改變新抗原的發現過程，從而實現更快、更準確的預測並推動市場發展勢頭。這個市場的本質是高度動態的，受到快速的技術進步和不斷變化的監管環境的推動。相關人員應專注於產生可靠的臨床試驗和真實世界證據，以證明治療的有效性和安全性，同時遵守國際監管標準。基因組研究的持續創新，加上精準腫瘤學的策略定位，為公司提供了成長途徑。生技公司、醫療保健提供者和監管機構之間的合作網路可以促進簡化開發途徑並加快向患者提供突破性治療方法。

主要市場統計
基準年[2023] 33.1億美元
預測年份 [2024] 45.8億美元
預測年份 [2030] 324.1億美元
複合年成長率（%） 38.52%

市場動態：快速發展的新抗原標靶治療市場的關鍵市場洞察

新抗原標靶治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 新抗原標靶治療越來越受歡迎
    • 癌症患者急劇增加
    • 世界老年人口的增加
    • 醫療基礎建設發展
  • 市場限制因素
    • 與新抗原標靶治療藥物相關的副作用
  • 市場機會
    • 癌症治療的技術進步
    • 加大贖回制度等政府投入
  • 市場挑戰
    • 新抗原鑑定的挑戰

波特五力：引領新抗原標靶治療治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解新抗原標靶治療治療市場的外部影響

外部宏觀環境因素在塑造新抗原標靶治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解新抗原標靶治療藥物市場的競爭狀況

對新抗原標靶治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣新抗原標靶治療治療市場供應商的績效評估

FPNV定位矩陣是評估新抗原標靶治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪新抗原標靶治療市場的成功之路

新抗原標靶治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 新抗原標靶治療越來越受歡迎
      • 癌症患者數量迅速增加
      • 世界各地老年人口不斷成長
      • 發展醫療保健基礎設施
    • 抑制因素
      • 與新抗原標靶治療相關的副作用
    • 機會
      • 癌症治療的技術進步
      • 增加政府投資，包括贖回計劃
    • 任務
      • 新抗原鑑定的挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以目標疾病適應症分類的新抗原標標靶治療治療市場

  • 骨癌
  • 大腸直腸癌
  • 婦科癌症
  • 非小細胞肺癌
  • 腎臟細胞癌

第7章新抗原標靶治療藥物市場（以新抗原類型分類）

  • 現成的新抗原
  • 個人化新抗原

第8章以免疫治療類型分類的新抗原標靶治療治療市場

  • 樹突細胞疫苗
  • 基於 DNA/RNA 的疫苗
  • 蛋白質/勝胜肽疫苗
  • 基於 TIL 的治療方法

第9章新抗原標靶治療治療市場：依給藥途徑

  • 皮內
  • 靜脈
  • 皮下的

第10章美洲新抗原標靶治療治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區新抗原標靶治療治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲新抗原標靶治療治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Achilles Therapeutics PLC
  • Advaxis, Inc.
  • Bavarian Nordic
  • BioNTech SE
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genocea Biosciences, Inc.
  • Gradalis, Inc.
  • Gritstone bio, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Precision Biologics
Product Code: MRR-43078BB92C77

The Neoantigen Targeted Therapies Market was valued at USD 3.31 billion in 2023, expected to reach USD 4.58 billion in 2024, and is projected to grow at a CAGR of 38.52%, to USD 32.41 billion by 2030.

Neoantigen-targeted therapies focus on creating personalized cancer vaccines and adoptive T cell therapies by exploiting neoantigens, which are unique to cancer cells due to tumor-specific mutations. These therapies hold immense necessity as they offer the potential for enhanced specificity and effectiveness with reduced off-target effects compared to traditional treatments. Application spans personalized medicine, where treatments are tailored to individual patients based on genetic profiling. End-use sectors include hospitals, cancer research centers, and pharmaceutical companies working towards large-scale clinical applications. Key growth factors influencing this market include the increasing prevalence of cancer, advancements in genomic technologies, and heightened investments in personalized medicine. The rising adoption of next-generation sequencing and bioinformatics tools enhances neoantigen identification, representing significant opportunities. Pharmaceutical companies and research institutions should focus on strategic collaborations to harness bioinformatics capabilities and genomic databases effectively, optimizing neoantigen prediction and validation. However, challenges such as the high cost of therapies, complexity in neoantigen identification, and stringent regulatory frameworks could impede market growth. Overcoming these barriers necessitates innovation particularly in automated bioinformatics analysis and cost-effective production techniques to enhance accessibility. Investment in adaptive AI/machine learning models could revolutionize neoantigen discovery processes, allowing for faster and more accurate predictions, propelling market momentum. The nature of this market is highly dynamic, driven by rapid technological advancements and evolving regulatory landscapes. Stakeholders should emphasize robust clinical trials and real-world evidence generation to substantiate therapy efficacy and safety while remaining compliant with international regulatory standards. Constant innovation in genomic research, coupled with strategic positioning within precision oncology, offers businesses an avenue for growth. Collaborative networks between biotech firms, healthcare providers, and regulatory bodies can facilitate a streamlined developmental pathway and expedite the provision of these groundbreaking therapies to patients, thus capturing a larger market share in this emergent therapeutic frontier.

KEY MARKET STATISTICS
Base Year [2023] USD 3.31 billion
Estimated Year [2024] USD 4.58 billion
Forecast Year [2030] USD 32.41 billion
CAGR (%) 38.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the popularity of neoantigen targeted therapies
    • Surge in number of cancer patients
    • Increase in the geriatric population across the globe
    • Developing healthcare infrastructure
  • Market Restraints
    • Side effects associated with neoantigen targeted therapies
  • Market Opportunities
    • Technological advancement in the cancer treatment
    • Increasing government investment such as reimbursement plan
  • Market Challenges
    • Challenges of neoantigen identification

Porter's Five Forces: A Strategic Tool for Navigating the Neoantigen Targeted Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neoantigen Targeted Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neoantigen Targeted Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neoantigen Targeted Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neoantigen Targeted Therapies Market

A detailed market share analysis in the Neoantigen Targeted Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neoantigen Targeted Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neoantigen Targeted Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neoantigen Targeted Therapies Market

A strategic analysis of the Neoantigen Targeted Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Targeted Therapies Market, highlighting leading vendors and their innovative profiles. These include Achilles Therapeutics PLC, Advaxis, Inc., Bavarian Nordic, BioNTech SE, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genocea Biosciences, Inc., Gradalis, Inc., Gritstone bio, Inc., IOVANCE Biotherapeutics, Inc., ISA Pharmaceuticals B.V., Medigene AG, Merck & Co., Inc., and Precision Biologics.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Targeted Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Target Disease Indication, market is studied across Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, and Renal Cell Carcinoma.
  • Based on Neoantigens Type, market is studied across Off-the-Shelf Neoantigens and Personalized Neoantigens.
  • Based on Immunotherapy Type, market is studied across Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, and TIL-Based Therapies.
  • Based on Route of Administration, market is studied across Intradermal, Intravenous, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the popularity of neoantigen targeted therapies
      • 5.1.1.2. Surge in number of cancer patients
      • 5.1.1.3. Increase in the geriatric population across the globe
      • 5.1.1.4. Developing healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with neoantigen targeted therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the cancer treatment
      • 5.1.3.2. Increasing government investment such as reimbursement plan
    • 5.1.4. Challenges
      • 5.1.4.1. Challenges of neoantigen identification
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neoantigen Targeted Therapies Market, by Target Disease Indication

  • 6.1. Introduction
  • 6.2. Bone Cancer
  • 6.3. Colorectal Cancer
  • 6.4. Gynecological Cancer
  • 6.5. Non-Small Cell Lung Cancer
  • 6.6. Renal Cell Carcinoma

7. Neoantigen Targeted Therapies Market, by Neoantigens Type

  • 7.1. Introduction
  • 7.2. Off-the-Shelf Neoantigens
  • 7.3. Personalized Neoantigens

8. Neoantigen Targeted Therapies Market, by Immunotherapy Type

  • 8.1. Introduction
  • 8.2. Dendritic Cell Vaccines
  • 8.3. DNA / RNA-Based Vaccines
  • 8.4. Protein / Peptide-based Vaccines
  • 8.5. TIL-Based Therapies

9. Neoantigen Targeted Therapies Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intradermal
  • 9.3. Intravenous
  • 9.4. Subcutaneous

10. Americas Neoantigen Targeted Therapies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Neoantigen Targeted Therapies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Neoantigen Targeted Therapies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Achilles Therapeutics PLC
  • 2. Advaxis, Inc.
  • 3. Bavarian Nordic
  • 4. BioNTech SE
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Genocea Biosciences, Inc.
  • 8. Gradalis, Inc.
  • 9. Gritstone bio, Inc.
  • 10. IOVANCE Biotherapeutics, Inc.
  • 11. ISA Pharmaceuticals B.V.
  • 12. Medigene AG
  • 13. Merck & Co., Inc.
  • 14. Precision Biologics

LIST OF FIGURES

  • FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEOANTIGEN TARGETED THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023